8-K
filed April 3, 2023, 7:59 PM ET
ticker BTCY
CIK 0001630113
other material
confidence high
sentiment neutral
materiality 0.50
Biotricity shareholders approve 2023 equity plans, reverse split up to 1:10, and $10M convertible note issuance
BIOTRICITY INC.
- Approved 2023 Equity Incentive Plan reserving 5M shares plus any unissued from 2016 plan (15.7M votes for).
- Authorized reverse stock split within 1:2 to 1:10 ratio, with Board discretion to implement within one year (27.5M for).
- Approved potential issuance of up to $10M common stock upon conversion of convertible notes (17.3M for, 629.8K against).
- Ratified SRCO Professional Corporation as independent auditor for FY ending March 31, 2023 (28.7M for).
- Directors elected: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, Chester White.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation.
- Proposal
- say on pay frequency
- Outcome
- passed
Exact text from the filing
Year Abstain 5,211,232 189,147 12,566,007 120,883 7. The Company’s stockholders approved and ratified the Company’s 2023 Employee Stock Purchase Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Approval and ratification of the Company’s 2023 Employee Stock Purchase Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved and ratified the Company’s 2023 Employee Stock Purchase Plan
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Approval of potential issuance of securities of up to $10,000,000 of common stock upon conversion of convertible promissory notes.
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved the potential issuance of securities
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Approval to grant discretionary authority to the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-10.
- Proposal
- reverse split
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved the vote to grant discretionary authority
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Ratification of the appointment of SRCO Professional Corporation as the independent registered public accounting firm for the period ending March 31, 2023.
- Proposal
- auditor ratification
- Outcome
- passed
Exact text from the filing
The Company’s stockholders ratified the appointment of SRCO Professional Corporation
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Advisory non-binding vote to approve the compensation of the named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
The Company’s stockholder held an advisory non-binding vote to approve the compensation
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Election of six directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Director Nominee Votes For Votes Against Votes Withheld Waqaas Al-Siddiq 17,934,880 10,746,690 152,389 David A. Rosa 16,201,827 10,746,690 1,885,442 Ronald McClurg 18,028,722 10,746,690 58,547 Chester White 17,628,790 10,746,690 458,479
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
BIOTRICITY INC. shareholders approved Approval and ratification of the Company’s 2023 Equity Incentive Plan, including the reservation of 5,000,000 shares of common stock.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved and ratified the Company’s 2023 Equity Incentive Plan
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.